# Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

> **NCT07165886** · PHASE2,PHASE3 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 298 (estimated)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Sirolimus for injection (albumin bound)
- **DRUG:** Octreotide long-acting injection
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT07165886
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2028-08-29
- **Final completion:** 2028-08-29
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07165886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07165886, "Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07165886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*